🧪 Beta — BiohacksAI is under active development. Data and features may change.
B
BiohacksAI
Evidence-Based Biohacking
BetaPatent Pending

TAOK2

MOLECULAR TARGET

TAO kinase 2

UniProt: Q9UL54NCBI Gene: 934429 compounds

TAOK2 (TAO kinase 2) is targeted by 29 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting TAOK2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1alvocidib4.5291
2foretinib4.3476
3tozasertib4.3375
4ruxolitinib4.2368
5palbociclib4.2267
6bosutinib4.0858
7dinaciclib3.8747
8pazopanib3.6939
9bms 3870323.4731
10tae 6843.4330
11fedratinib3.4029
12gilteritinib3.4029
13at 75193.3327
14lestaurtinib3.0420
15pacritinib3.0420
16ruboxistaurin2.9418
17r 4062.8316
18cediranib2.8316
19milciclib2.7715
20pha 6657522.7114
21gsk 6906932.6413
22ast 4872.5612
23zotiraciclib2.5612
24raf 2652.4811
25golvatinib2.208
26rg 5472.087
27pf 038147351.795
28Crizotinib0.691
29Sorafenib0.691

About TAOK2 as a Drug Target

TAOK2 (TAO kinase 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 29 compounds with documented TAOK2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

TAOK2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.